Innovative Medicines

As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.

Novartis’s Innovative Medicines Business in Q2 2018

The above chart compares the revenues for Innovative Medicines since the first quarter of 2017. Let’s look next at franchise product revenues.

Pharmaceuticals

Ophthalmology products reported a 1% decrease in revenues YoY to ~$1.2 billion in Q2 2018, driven by lower sales of products from the Topical Olopatadine group, the Travoprost group, and other products, partially offset by strong sales of Lucentis.

Neuroscience products reported a 3% growth in revenues YoY to $889 million in Q2 2018 following strong sales for Gilenya.

Immunology, hepatology, and dermatology products reported a 41% growth in revenues YoY to $833 million in Q2 2018 following strong sales of Cosentyx and Ilaris.

Respiratory products reported a 14% growth in revenues YoY to $433 million in Q2 2018 following strong sales of Seebri Breezhaler, Ultibro Breezhaler, Xolair, and other respiratory products, partially offset by lower sales of Onbrez Breezhaler.

Cardiometabolic products reported ~100% growth in revenues YoY to $245 million in Q2 2018, driven by strong sales of Entresto and other products.

Established products reported a 1% decline in revenues YoY to $1.8 billion in Q2 2018.

Novartis Oncology

Oncology products reported a 12% growth in revenues YoY to $3.4 billion in Q2 2018, driven by strong sales of Tafinlar and Mekinist, Tasigna, Afinitor/Votubia, Promacta/Revolade, Votrient, Exjade/Jadenu, Kisqali, Jakavi, and Kymriah, substantially offset by lower sales of Gleevec/Glivec, Sandostatin, and other oncology products.

The Invesco BLDRS Developed Markets 100 ADR ETF (ADRD) holds 5.3% of its total investments in Novartis ADR (NVS), 2.5% in GlaxoSmithKline ADR (GSK), 2.5% in Sanofi ADR (SNY), and 2.4% in AstraZeneca ADR (AZN).

Latest articles

15 Jul

Will Amazon Prime Day 2019 Break 2018's Record?

WRITTEN BY Jitendra Parashar

This year, Amazon extended its Prime Day to 48 hours instead of the 36-hour sale in July 2018, making the 2019 event the longest Prime Day ever.

In a series of tweets on Monday, Trump today weighed in on China’s GDP growth, which came in at a 27-year low.

15 Jul

OrganiGram's Third-Quarter Earnings

WRITTEN BY Adam Jones

On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

Trump is reportedly planning to increase the content of US-made steel in federal projects, which would be a lifeline for US steel companies.

Huawei is preparing for “extensive layoffs” in the US, which could put the US-China trade deal on the rocks.

With Q2's Netflix earnings just around the corner, here's what you can expect from the online streaming giant and the broader streaming space.